作者更正：尼达尼布对特发性肺纤维化患者的胃肠道不良反应及相关危险因素
Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis.
作者信息
Kato Motoyasu, Sasaki Shinichi, Nakamura Takahiro, Kurokawa Kana, Yamada Tomoko, Ochi Yusuke, Ihara Hiroaki, Takahashi Fumiyuki, Takahashi Kazuhisa
机构信息
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Department of Respiratory Medicine, Juntendo University Urayasu Hospital, Urayasu, Chiba, Japan.
出版信息
Sci Rep. 2020 Jul 16;10(1):12080. doi: 10.1038/s41598-020-69088-7.
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
摘要
本文的一个修订版本已发表，可通过本文顶部的链接获取。
相似文献
1
Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis.作者更正：尼达尼布对特发性肺纤维化患者的胃肠道不良反应及相关危险因素
Sci Rep. 2020 Jul 16;10(1):12080. doi: 10.1038/s41598-020-69088-7.
2
Author Correction: Imaging and Pathological Features of Idiopathic Portal Hypertension and Differential Diagnosis from Liver Cirrhosis.作者更正：特发性门静脉高压的影像学及病理特征与肝硬化的鉴别诊断
Sci Rep. 2020 Apr 30;10(1):7586. doi: 10.1038/s41598-020-63868-x.
3
Author Correction: Targeting cardiac fibrosis with engineered T cells.作者更正：利用工程化T细胞靶向心脏纤维化。
Nature. 2019 Dec;576(7785):E2. doi: 10.1038/s41586-019-1761-7.
4
Author Correction: Arginyltransferase knockdown attenuates cardiac hypertrophy and fibrosis through TAK1-JNK1/2 pathway.作者更正：精氨酰转移酶敲低通过TAK1-JNK1/2途径减轻心脏肥大和纤维化。
Sci Rep. 2020 Jun 25;10(1):10662. doi: 10.1038/s41598-020-67556-8.
5
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.尼达尼布治疗特发性肺纤维化患者的长期安全性和耐受性：开放标签扩展研究 INPULSIS-ON 的结果。
Lancet Respir Med. 2019 Jan;7(1):60-68. doi: 10.1016/S2213-2600(18)30339-4. Epub 2018 Sep 14.
6
Author Correction: Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis.作者更正：气道表面液体酸化引发囊性纤维化中的宿主防御异常。
Sci Rep. 2019 Nov 21;9(1):17535. doi: 10.1038/s41598-019-54253-4.
7
Author Correction: ENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice.作者更正：ENMD - 1068通过减弱小鼠体内的TGF-β1/Smad2/3信号传导来抑制肝纤维化。
Sci Rep. 2019 Dec 10;9(1):19125. doi: 10.1038/s41598-019-55877-2.
8
Author Correction: Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing.作者更正：通过AsCas12a基因组编辑对囊性纤维化中的剪接突变进行等位基因特异性修复。
Nat Commun. 2020 Oct 22;11(1):5457. doi: 10.1038/s41467-020-19351-2.
9
Author Correction: Effects of the serine protease inhibitor rBmTI-A in an experimental mouse model of chronic allergic pulmonary inflammation.作者更正：丝氨酸蛋白酶抑制剂rBmTI-A在慢性过敏性肺部炎症实验小鼠模型中的作用
Sci Rep. 2019 Nov 13;9(1):17011. doi: 10.1038/s41598-019-53742-w.
10
Author Correction: A possible association between fructose consumption and pulmonary emphysema.作者更正：果糖摄入与肺气肿之间可能存在的关联。
Sci Rep. 2020 Sep 25;10(1):16158. doi: 10.1038/s41598-020-69892-1.
引用本文的文献
1
Disproportionality Analysis of Hepatotoxic and Gastrointestinal Adverse Events Associated With Nintedanib Using the Japanese Adverse Drug Event Report (JADER) Database.使用日本药品不良事件报告（JADER）数据库对与尼达尼布相关的肝毒性和胃肠道不良事件进行不成比例分析。
In Vivo. 2025 Jan-Feb;39(1):396-403. doi: 10.21873/invivo.13841.
2
Clinical significance of high monocyte counts for the continuous treatment with nintedanib.高单核细胞计数对尼达尼布持续治疗的临床意义。
BMC Pulm Med. 2023 Jul 3;23(1):242. doi: 10.1186/s12890-023-02536-y.
3
Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases.脂质体改善肺泡疾病吸入药物递送的机制。
Adv Nanobiomed Res. 2023 Mar;3(3):2200106. doi: 10.1002/anbr.202200106. Epub 2023 Jan 27.
Zotero 插件